Ultimately, there is a pressing need to understand whether the beneficial indirect effects of GLP-1RA medications on pancreatic diseases, including PDAC (e.g., weight loss), are negated by direct effects on the pancreas
In preclinical research, this combination formulation is being examined for coordinated effects on inflammation regulation, angiogenesis, fibroblast activity, and cellular stress responses
Meier JJ, Rosenstock J, Hincelin-Mery A, Roy-Duval C, Delfolie A, Coester HV, et al
*Correspondence: Hitoshi Ando, [email protected] This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
adults were taking GLP-1 medications as of November to lose weight or treat a chronic condition like diabetes, according to a study by the Kaiser Family Foundation
We help you choose the right option during your visit